Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation

Clinical Transplantation

Volumn 18, Issue 4, 2004, Pages 402-406

  Ciancio, Gaetano ^a   Burke, George W ^a   Mattiazi, Adela ^a   Leibovici, Zvi ^a   Dowdy, Lorraine ^a   Roth, David ^a   Kupin, Warren ^a   Rosen, Anne ^a   Jorge, Delvis ^a   Cirocco, Robert E ^a   Miller, Joshua ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Kidney; Pancreas; Transplantation; Valganciclovir

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; HEPATITIS; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PANCREAS TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; STANDARD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 4043109117     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00180.x     Document Type: Article

References (21)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741.
2. Rubin RH. Clinical approach to infection in the compromised host. In: Rubin RH, Young LS, eds. Infection in the Organ Transplant Recipient. New York, NY: Kluwer Academic Press, 2002: 573.
3. Lowance D, Neumayer HH, Legendre CM et al. for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999: 340: 1462.
4. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000: 13: 83.
5. Rubin RH, Ikonen T, Gummert JF, Morris RE. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1999: 1: 29.
6. Isenberg AL, Shen GK, Singh TP, Hahn A, Conti DJ. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy. Clin Transpl 2000: 14: 193.
7. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001: 12: 848.
8. Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002: 39: 1088.
9. Chou S. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001: 3: 20.
10. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000: 356: 645.
11. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000: 44: 2811.
12. Curran M, Noble S. Valganciclovir. Drugs 2001: 61: 1145.
13. Martin DF, Sierra-Madero J, Walmsley S et al. for the Valganciclovir Study Group. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002: 346: 1119.
14. Paya CV on behalf of the Valganciclovir Solid Organ Transplant Study Group. A randomized, double-blind, double-dummy, active-comparator controlled multicenter study of the efficacy and safety of valganciclovir vs oral ganciclovir for prevention of CMV disease in 372 D + /R-heart, liver, and kidney recipients. Poster presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, California.
15. Cirocco RE, Ciancio G, Esquenazi V, Burke GW, Miller J. Kidney recipient CMV incidence in the ganciclovir era; monitoring viral DNA by a CMV-PCR assay. Transpl Proc 1999: 31: 1362.
16. Valantine HA, Gao SZ, Menon SG et al. Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999: 100: 61.
17. Orens JB. Cytomegalovirus prophylaxis with IV ganciclovir in lung transplant recipients:the long and the short of it! Chest 1999: 116: 1152.
18. Sageda S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transpl 2002: 2: 850.
19. Hengster P, Pescovitz MD, Hyatt D, Margreiter R. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Transplantation 1999: 68: 310.
20. Razonable RR, Rivero A, Rodriguez A et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001: 184: 1461.
21. Kunzle N, Petignat C, Francioli P et al. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity. Transpl Infect Dis 2000: 2: 118.